Pharmacological interventions for people with borderline personality disorder
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among people with a diagnosis of borderline personality disorder (BPD) who are engaged in clinical care, prescription rates of psychotropic medications are high, despite the fact that medication use is off-label as a treatment for BPD. Nevertheless, people with BPD often receive several psychotropic drugs at a time for sustained periods. OBJECTIVES: To assess the effects of pharmacological treatment for people with BPD. SEARCH METHODS: For this update, we searched CENTRAL, MEDLINE, Embase, 14 other databases and four trials registers up to February 2022. We contacted researchers working in the field to ask for additional data from published and unpublished trials, and handsearched relevant journals. We did not restrict the search by year of publication, language or type of publication. SELECTION CRITERIA: Randomised controlled trials comparing pharmacological treatment to placebo, other pharmacologic treatments or a combination of pharmacologic treatments in people of all ages with a formal diagnosis of BPD. The primary outcomes were BPD symptom severity, self-harm, suicide-related outcomes, and psychosocial functioning. Secondary outcomes were individual BPD symptoms, depression, attrition and adverse events. DATA COLLECTION AND ANALYSIS: At least two review authors independently selected trials, extracted data, assessed risk of bias using Cochrane's risk of bias tool and assessed the certainty of the evidence using the GRADE approach. We performed data analysis using Review Manager 5 and quantified the statistical reliability of the data using Trial Sequential Analysis. MAIN RESULTS: We included 46 randomised controlled trials (2769 participants) in this review, 45 of which were eligible for quantitative analysis and comprised 2752 participants with BPD in total. This is 18 more trials than the 2010 review on this topic. Participants were predominantly female except for one trial that included men only. The mean age ranged from 16.2 to 39.7 years across the included trials. Twenty-nine different types of medications compared to placebo or other medications were included in the analyses. Seventeen trials were funded or partially funded by the pharmaceutical industry, 10 were funded by universities or research foundations, eight received no funding, and 11 had unclear funding. For all reported effect sizes, negative effect estimates indicate beneficial effects by active medication. Compared with placebo, no difference in effects were observed on any of the primary outcomes at the end of treatment for any medication. Compared with placebo, medication may have little to no effect on BPD symptom severity, although the evidence is of very low certainty (antipsychotics: SMD -0.18, 95% confidence interval (CI) -0.45 to 0.08; 8 trials, 951 participants; antidepressants: SMD -0.27, 95% CI -0.65 to 1.18; 2 trials, 87 participants; mood stabilisers: SMD -0.07, 95% CI -0.43 to 0.57; 4 trials, 265 participants). The evidence is very uncertain about the effect of medication compared with placebo on self-harm, indicating little to no effect (antipsychotics: RR 0.66, 95% CI 0.15 to 2.84; 2 trials, 76 participants; antidepressants: MD 0.45 points on the Overt Aggression Scale-Modified-Self-Injury item (0-5 points), 95% CI -10.55 to 11.45; 1 trial, 20 participants; mood stabilisers: RR 1.08, 95% CI 0.79 to 1.48; 1 trial, 276 participants). The evidence is also very uncertain about the effect of medication compared with placebo on suicide-related outcomes, with little to no effect (antipsychotics: SMD 0.05, 95 % CI -0.18 to 0.29; 7 trials, 854 participants; antidepressants: SMD -0.26, 95% CI -1.62 to 1.09; 2 trials, 45 participants; mood stabilisers: SMD -0.36, 95% CI -1.96 to 1.25; 2 trials, 44 participants). Very low-certainty evidence shows little to no difference between medication and placebo on psychosocial functioning (antipsychotics: SMD -0.16, 95% CI -0.33 to 0.00; 7 trials, 904 participants; antidepressants: SMD -0.25, 95% CI -0.57 to 0.06; 4 trials, 161 participants; mood stabilisers: SMD -0.01, 95% CI -0.28 to 0.26; 2 trials, 214 participants). Low-certainty evidence suggests that antipsychotics may slightly reduce interpersonal problems (SMD -0.21, 95% CI -0.34 to -0.08; 8 trials, 907 participants), and that mood stabilisers may result in a reduction in this outcome (SMD -0.58, 95% CI -1.14 to -0.02; 4 trials, 300 participants). Antidepressants may have little to no effect on interpersonal problems, but the corresponding evidence is very uncertain (SMD -0.07, 95% CI -0.69 to 0.55; 2 trials, 119 participants). The evidence is very uncertain about dropout rates compared with placebo by antipsychotics (RR 1.11, 95% CI 0.89 to 1.38; 13 trials, 1216 participants). Low-certainty evidence suggests there may be no difference in dropout rates between antidepressants (RR 1.07, 95% CI 0.65 to 1.76; 6 trials, 289 participants) and mood stabilisers (RR 0.89, 95% CI 0.69 to 1.15; 9 trials, 530 participants), compa
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
Development, reliability, and validity of a dissociation scale
BERNSTEIN, E. M., & PUTNAM, F. W. (1986) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198612000-00004 · Cited by 3,793
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Assessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
GRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693
Research works printed but not linked: 220
- Amminger, 2013, Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial, Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie], 58, 402, 10.1177/070674371305800705 · DOI · Paper page
- Van den Broek, 2008, P.3.c.038. The effect of quetiapine on psychotic-like symptoms in borderline personality disorder. A placebo-controlled trial, European Neuropsychopharmacology, 18, S425, 10.1016/S0924-977X(08)70622-9 · doi:10.1016/s0924-977x(08)70622-9
- Bellino, 2013, Omega-3 fatty acids associated with valproate in the treatment of borderline personality disorder: a controlled study, Journal of Psychopathology, 19, 296
- Bellino, 2014, Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid, Journal of Psychopharmacology, 28, 125, 10.1177/0269881113510072 · DOI
- Bozzatello, 2018, Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: a follow-up study, Clinical Drug Investigation, 38, 367, 10.1007/s40261-017-0617-x · DOI
- Bellino S Inclusion of study in Cochrane review Email to: A Tadorovac
- Black, 2014, Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial, American Journal of Psychiatry, 171, 1174, 10.1176/appi.ajp.2014.13101348 · DOI · Paper page
- Lee, 2016, Quetiapine's effect on the SCL-90-R domains in patients with borderline personality disorder, Annals of Clinical Psychiatry, 28, 4
- Bogenschutz, 2004, Olanzapine versus placebo in the treatment of borderline personality disorder, Journal of Clinical Psychiatry, 65, 104, 10.4088/jcp.v65n0118 · DOI · Paper page
- Bozzatello, 2017, Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial, Central Nervous System Drugs, 31, 801, 10.1007/s40263-017-0458-4 · DOI
- Cowdry, 1988, Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine, Archives of General Psychiatry, 45, 111, 10.1001/archpsyc.1988.01800260015002 · DOI · Paper page
- Gardner, 1985, Alprazolam-induced dyscontrol in borderline personality disorder, American Journal of Psychiatry, 142, 98, 10.1176/ajp.142.1.98 · DOI · Paper page
- Gardner, 1986, Development of melancholia during carbamazepine treatment in borderline personality disorder, Journal of Clinical Psychopharmacology, 6, 236, 10.1097/00004714-198608000-00008 · DOI
- Gardner, 1986, Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder, American Journal of Psychiatry, 143, 519, 10.1176/ajp.143.4.519 · DOI
- Crawford, 2015, Lamotrigine versus inert placebo in the treatment of borderline personality disorder: study protocol for a randomized controlled trial and economic evaluation, Trials, 16, 308, 10.1186/s13063-015-0823-x · DOI
- Crawford, 2018, Lamotrigine for people with borderline personality disorder: a RCT, Health Technology Assessment, 22, 1, 10.3310/hta22170 · DOI
- Crawford MJ Inclusion of your study in Cochrane review Email to: A Pathmanathan Ratnam
- De la Fuente, 1994, A trial of carbamazepine in borderline personality disorder, European Neuropsychopharmacology, 4, 479, 10.1016/0924-977x(94)90296-8 · DOI
- De la Fuente, 1993, Carbamazepine in borderline personality disorder, European Neuropsychopharmacology, 3, 350, 10.1016/0924-977X(93)90132-6 · DOI
- Goldberg, 1986, Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo, Archives of General Psychiatry, 43, 680, 10.1001/archpsyc.1986.01800070070009 · DOI · Paper page
- Grant, 2022, A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder, British Journal of Psychiatry, 220, 58, 10.1192/bjp.2021.159 · DOI
- Hallahan, 2007, Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial, British Journal of Psychiatry, 190, 118, 10.1192/bjp.bp.106.022707 · DOI · Paper page
- Hollander, 2001, A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder, Journal of Clinical Psychiatry, 62, 199, 10.4088/jcp.v62n0311 · DOI · Paper page
- Jariani, 2010, The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy, Psychiatria Danubina, 22, 544
- Kulkarni, 2018, Effect of the glutamate NMDA receptor antagonist memantine as adjunctive treatment in borderline personality disorder: an exploratory, randomised, double-blind, placebo-controlled trial, Central Nervous System Drugs, 32, 179, 10.1007/s40263-018-0506-8 · DOI
- Leone, 1982, Response of borderline patients to loxapine and chlorpromazine, Journal of Clinical Psychiatry, 43, 148
- Linehan, 2008, Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study, Journal of Clinical Psychiatry, 69, 999, 10.4088/jcp.v69n0617 · DOI · Paper page
- Loew, 2006, Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study, Journal of Clinical Psychopharmacology, 26, 61, 10.1097/01.jcp.0000195113.61291.48 · DOI · Paper page
- Loew, 2008, Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up, Journal of Clinical Psychopharmacology, 28, 355, 10.1097/JCP.0b013e318173a8fb · DOI
- Markovitz, 1995, Impulsivity and Aggression, 263
- Moen, 2012, Efficacy of extended-release divalproex combined with "condensed" dialectical behavior therapy for individuals with borderline personality disorder, Annals of Clinical Psychiatry, 24, 255
- Montgomery, 1982, Pharmacological prevention of suicidal behaviour, Journal of Affective Disorders, 4, 291, 10.1016/0165-0327(82)90026-x · DOI · Paper page
- Montgomery, 1983, Depression and Suicide: Aspects Medicaux, Psychologiques et Socio-Culturels, 786, 10.1016/B978-0-08-027080-7.50130-0 · DOI
- Montgomery, 1982, Pharmacological prevention of suicidal behaviour, Journal of Affective Disorders, 4, 291, 10.1016/0165-0327(82)90026-x · DOI · Paper page
- Montgomery, 1983, The prevention of recurrent suicidal acts, British Journal of Clinical Pharmacology, 15, 183, 10.1111/j.1365-2125.1983.tb05864.x · DOI · Paper page
- Fertuck, 2012, Higher executive control and visual memory performance predict treatment completion in borderline personality disorder, Psychotherapy and Psychosomatics, 81, 38, 10.1159/000329700 · DOI · Paper page
- Nickel, 2007, Topiramate reduced aggression in female patients with borderline personality disorder, European Archives of Psychiatry and Clinical Neuroscience, 257, 432, 10.1007/s00406-007-0735-1 · DOI
- Nickel, 2004, Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study, Journal of Clinical Psychiatry, 65, 1515, 10.4088/jcp.v65n1112 · DOI · Paper page
- Nickel, 2008, Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up, European Psychiatry, 23, 115, 10.1016/j.eurpsy.2007.09.004 · DOI · Paper page
- Nickel, 2005, Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study, Biological Psychiatry, 57, 495, 10.1016/j.biopsych.2004.11.044 · DOI · Paper page
- Nickel, 2007, Topiramate treatment of aggression in male borderline patients, Australian and New Zealand Journal of Psychiatry, 41, 461, 10.1080/00048670701261251 · DOI · Paper page
- Nickel, 2007, Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up, Psychopharmacology, 191, 1023, 10.1007/s00213-007-0740-0 · DOI
- Nickel, 2006, Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study, American Journal of Psychiatry, 163, 833, 10.1176/ajp.2006.163.5.833 · DOI · Paper page
- Nickel, 2007, Aripiprazole treatment of patients with borderline personality disorder, Journal of Clinical Psychiatry, 68, 1815, 10.4088/jcp.v68n1124f · DOI
- Pascual, 2008, Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study, Journal of Clinical Psychiatry, 69, 603, 10.4088/JCP.v69n0412 · DOI · Paper page
- Reich, 2009, A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder, International Clinical Psychopharmacology, 24, 270, 10.1097/YIC.0b013e32832d6c2f · DOI · Paper page
- Rinne, 2002, SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder, American Journal of Psychiatry, 159, 2048, 10.1176/appi.ajp.159.12.2048 · DOI · Paper page
- Salzmann, 1995, Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder, Journal of Clinical Psychopharmacology, 15, 23, 10.1097/00004714-199502000-00005 · DOI · Paper page
- Schmahl, 2012, Evaluation of naltrexone for dissociative symptoms in borderline personality disorder, International Clinical Psychopharmacology, 27, 61, 10.1097/YIC.0b013e32834d0e50 · DOI · Paper page
- Schulz, 2006, P02.101 Olanzapine for the treatment of borderline personality disorder: a flexible-dose 12-week randomized double-blind placebo-controlled study, International Journal of Neuropsychopharmacology, 9, S191, 10.1017/S1461145706007292 · doi:10.1017/s1461145706007292
- Schulz, 2008, Olanzapine for the treatment of borderline personality disorder: variable dose, 12-week randomised double-blind placebo-controlled study, British Journal of Psychiatry, 193, 485, 10.1192/bjp.bp.107.037903 · DOI · Paper page
- Schulz SC Zanarini MC Detke HC Trzaskoma Q Lin D DeBerdt W Olanzapine for the treatment of borderline personality disorder: a flexible-dose, 12-week, randomized, double-blind, placebo-controlled study Association of European Psychiatrsts. 15th European Congress of Psychiatry; 2007 Mar 17-21; Madrid, Spain 2007 · DOI
- Schulz, 2007, P248 Olanzapine for the treatment of borderline personality disorder: a flexible-dose 12-week randomized double-blind placebo-controlled study, European Psychiatry, 22, S172, 10.1016/j.eurpsy.2007.01.564 · DOI
- Zanarini, 2006, 80. Olanzapine for the treatment of borderline personality disorder: two 12-week randomized double-blind placebo-controlled trials, Neuropsychopharmacology, 31, S229, 10.1017/S1461145706007292 · doi:10.1017/s1461145706007292
- Shafti, 2010, Olanzapine versus haloperidol in the management of borderline personality disorder, Journal of Clinical Psychopharmacology, 30, 44, 10.1097/JCP.0b013e3181c826ff · DOI
- Shafti, 2015, A comparative study on olanzapine and aripiprazole for symptom management in female patients with borderline personality disorder, Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology], 25, 38, 10.5455/bcp.20140923100030 · doi:10.5455/bcp.20140923100030
- Shafti, 2014, Olanzapine vs aripiprazole in the management of borderline personality disorder, Current Psychopharmacology, 3, 132, 10.2174/2211556003666140912223626 · doi:10.2174/2211556003666140912223626
- Soloff, 1987, Behavioral dyscontrol in borderline patients treated with amitriptyline, Psychopharmacology Bulletin, 23, 177
- Soloff, 1986, Paradoxical effects of amitriptyline on borderline patients, American Journal of Psychiatry, 143, 1603, 10.1176/ajp.143.12.1603 · DOI · Paper page
- Soloff, 1986, Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo, Archives of General Psychiatry, 43, 691, 10.1001/archpsyc.1986.01800070081010 · DOI · Paper page
- Soloff, 1989, Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response, Journal of Clinical Psychopharmacology, 9, 238, 10.1097/00004714-198908000-00002 · DOI · Paper page
- Soloff, 1986, Amitriptyline and haloperidol in unstable and schizotypal borderline disorders, Psychopharmacology Bulletin, 22, 177
- Cornelius, 1993, Haloperidol vs phenelzine in continuation therapy of borderline disorder, Psychopharmacology Bulletin, 29, 333
- Cornelius, 1993, Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine, American Journal of Psychiatry, 150, 1843, 10.1176/ajp.150.12.1843 · DOI · Paper page
- Soloff, 1993, Efficacy of phenelzine and haloperidol in borderline personality disorder, Archives of General Psychiatry, 50, 377, 10.1001/archpsyc.1993.01820170055007 · DOI · Paper page
- Leiberich, 2008, Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up, Journal of Psychopharmacology, 22, 805, 10.1177/0269881107084004 · DOI · Paper page
- Tritt, 2005, Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study, Journal of Psychopharmacology, 19, 287, 10.1177/0269881105051540 · DOI · Paper page
- Zanarini, 2001, Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study, Journal of Clinical Psychiatry, 62, 849, 10.4088/jcp.v62n1103 · DOI · Paper page
- Zanarini, 2003, Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study, American Journal of Psychiatry, 160, 167, 10.1176/appi.ajp.160.1.167 · DOI · Paper page
- Zanarini, 2004, A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder, Journal of Clinical Psychiatry, 65, 903, 10.4088/jcp.v65n0704 · DOI · Paper page
- Zanarini, 2007, A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo controlled study, European Psychiatry, 22, S172, 10.1016/j.eurpsy.2007.01.565 · DOI
- Zanarini MC Schulz SC Detke HC Tanaka Y Zhao F Lin D A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study Association of European Psychiatrists. 15th European Congress of Psychiatry; 2007 Mar 17-21; Madrid, Spain 2007 · DOI
- Zanarini, 2006, P02.102 A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized double-blind placebo-controlled study, International Journal of Neuropsychopharmacology, 9, S191, 10.1017/S1461145706007450 · doi:10.1017/s1461145706007450
- Zanarini, 2006, 80. Olanzapine for the treatment of borderline personality disorder: two 12-week randomized double-blind placebo-controlled trials, Neuropsychopharmacology, 31, S229, 10.1017/S1461145706007292 · doi:10.1017/s1461145706007292
- Ziegenhorn, 2009, Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial, Journal of Clinical Psychopharmacology, 29, 170, 10.1097/JCP.0b013e31819a4bae · DOI · Paper page
- Coccaro, 1997, Fluoxetine and impulsive aggressive behavior in personality-disordered subjects, Archives of General Psychiatry, 54, 1081, 10.1001/archpsyc.1997.01830240035005 · DOI · Paper page
- Hollander, 2005, Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder, American Journal of Psychiatry, 162, 621, 10.1176/appi.ajp.162.3.621 · DOI · Paper page
- Hollander, 2003, Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders, Neuropsychopharmacology, 28, 1186, 10.1038/sj.npp.1300153 · DOI · Paper page
- Malevani J AW: Cochrane review: RCT zu Quetapin und Sertraline bei BPS [personal communication] Email to: J Stoffers-Winterling
- Koenigsberg, 2003, Risperidone in the treatment of schizotypal personality disorder, Journal of Clinical Psychiatry, 64, 628, 10.4088/jcp.v64n0602 · DOI · Paper page
- La Malfa, 2003, Aggressiveness and personality disorders: evaluation of efficacy and existence of predictors in the treatment with fluvoxamine and lithium, Minerva Psychiatrica, 44, 75
- Links, 1990, Lithium therapy for borderline patients: preliminary findings, Journal of Personality Disorders, 4, 173, 10.1521/pedi.1990.4.2.173 · DOI · Paper page
- Marchesi, 2006, Personality disorders and response to medication treatment in panic disorder: a 1-year naturalistic study, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 30, 1240, 10.1016/j.pnpbp.2006.03.010 · DOI
- Goodman M RE: [EXTERNAL] Cochrane Colllaboration review [personal communication] Email to: J Stoffers-Winterling
- McCloskey M Fwd: Cochrane Collaboration review - RCT of escitalopram in BPD Email to: J Stoffers-Winterling
- Parsons, 1989, Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression, Psychopharmacology Bulletin, 25, 524
- Rombold, 2014, Adjunctive lithium treatment in the prevention of suicidal behavior in patients with depression and comorbid personality disorders, International Journal of Psychiatry in Clinical Practice, 18, 300, 10.3109/13651501.2014.940052 · DOI
- Russell, 2003, Chronic depression and comorbid personality disorders: response to sertraline versus imipramine, Journal of Clinical Psychiatry, 64, 554, 10.4088/jcp.v64n0510 · DOI · Paper page
- Serban, 1984, Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol, American Journal of Psychiatry, 141, 1455, 10.1176/ajp.141.11.1455 · DOI · Paper page
- Verkes, 1998, Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression, American Journal of Psychiatry, 155, 543, 10.1176/ajp.155.4.543 · DOI · Paper page
- Wollmer, 2022, Clinical effects of glabellar botulinum toxin injections on borderline personality disorder: a randomized controlled trial, Journal of Psychopharmacology, 36, 159, 10.1177/02698811211069108 · DOI
- Arteaga-Henríquez, 2020, Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial, Trials, 21, 161, 10.1186/s13063-019-4040-x · DOI
- Chanen, 2019, Ripiprazole compared with placebo for auditory verbal hallucinations in youth with borderline personality disorder: protocol for the VERBATIM randomized controlled trial, Early Intervention in Psychiatry, 13, 1373, 10.1111/eip.12774 · DOI
- Aguglia, 2021, Off-label use of second-generation antipsychotics in borderline personality disorder: a survey of Italian psychiatrists, Journal of Personality Disorders, 35, 321, 10.1521/pedi_2019_33_445 · DOI
- Alvarez-Tomás, 2017, Long-term course of borderline personality disorder: a prospective 10-year follow-up study, Journal of Personality Disorders, 31, 590, 10.1521/pedi_2016_30_269 · DOI · Paper page
- Álvarez-Tomás, 2019, Long-term clinical and functional course of borderline personality disorder: a meta-analysis of prospective studies, European Psychiatry, 56, 75, 10.1016/j.eurpsy.2018.10.010 · DOI
- Amminger, 2010, Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial, Archives of General Psychiatry, 67, 146, 10.1001/archgenpsychiatry.2009.192 · DOI · Paper page
- Andrews, 2013, GRADE guidelines: 15. Going from evidence to recommendation - determinants of a recommendation’s direction and strength, Journal of Clinical Epidemiology, 66, 726-35, 10.1016/j.jclinepi.2013.02.003 · DOI · Paper page
- American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders (DSM-III)
- American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)
- American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
- American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)
- American Psychiatric Association, 2001, Practice guideline for the treatment of patients with borderline personality disorder, American Journal of Psychiatry, 158, 1
- American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 10.1176/appi.books.9780890425596 · DOI · Paper page
- Atkins, 2004, Grading quality of evidence and strength of recommendations, BMJ, 328, 1490, 10.1136/bmj.328.7454.1490 · DOI · Paper page
- Ayodeji, 2015, The influence of personality disorder on outcome in adolescent self-harm, British Journal of Psychiatry, 207, 313, 10.1192/bjp.bp.113.138941 · DOI · Paper page
- Barrett, 1995, Personality Characteristics of the Personality Disordered, 91
- Bateman, 2015, Treatment of personality disorder, Lancet, 385, 735, 10.1016/S0140-6736(14)61394-5 · DOI · Paper page
- Beck, 1961, An inventory for measuring depression, Archives of General Psychiatry, 4, 561, 10.1001/archpsyc.1961.01710120031004 · DOI · Paper page
- Bellino S Inclusion of study in Cochrane review Email to: A Tadorovac
- Berkey, 1996, Uncertainty of the time of first significance in random effects cumulative meta-analysis, Controlled Clinical Trials, 17, 357, 10.1016/S0197-2456(96)00014-1 · DOI
- Bero L Why the Cochrane risk of bias tool should include funding source as a standard item Cochrane Database of Systematic Reviews 2013 12 ED000075 10.1002/14651858.ED000075 24575439 · DOI · Paper page
- Biskin, 2015, The lifetime course of borderline personality disorder, Canadian Journal of Psychiatry, 60, 303, 10.1177/070674371506000702 · DOI · Paper page
- Black, 2014, Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial, American Journal of Psychiatry, 171, 1174, 10.1176/appi.ajp.2014.13101348 · DOI · Paper page
- Bode, 2017, Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data, European Journal of Health Economics, 18, 1125, 10.1007/s10198-016-0858-2 · DOI
- Bohus, 2021, Borderline personality disorder, Lancet, 398, 1528, 10.1016/S0140-6736(21)00476-1 · DOI · Paper page
- Borschmann, 2012, Crisis interventions for people with borderline personality disorder, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD009353.pub2 · DOI · Paper page
- Bridler, 2015, Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders, European Neuropsychopharmacology, 25, 763, 10.1016/j.euroneuro.2015.03.017 · DOI
- Brok, 2008, Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses, Journal of Clinical Epidemiology, 61, 763, 10.1016/j.jclinepi.2007.10.007 · DOI · Paper page
- Brok, 2009, Apparently conclusive meta-analysis may be inconclusive -- trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses, International Journal of Epidemiology, 38, 287, 10.1093/ije/dyn188 · DOI · Paper page
- Brühl, 2017, Neuroscience-based nomenclature: improving clinical and scientific terminology in research and clinical psychopharmacology, Psychological Medicine, 47, 1339, 10.1017/S0033291716003603 · DOI
- Brunetti, 2013, GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence, Journal of Clinical Epidemiology, 66, 140-50, 10.1016/j.jclinepi.2012.04.012 · DOI · Paper page
- Cailhol, 2015, Mental health service utilization among borderline personality disorder inpatients, L'Encéphale, 41, 115, 10.1016/j.encep.2014.10.008 · DOI
- Cavelti, 2019, Preliminary evidence for the cognitive model of auditory verbal hallucinations in youth with borderline personality disorder, Front Psychiatry, 10, 292, 10.3389/fpsyt.2019.00292 · DOI
- Cavelti, 2021, Psychotic symptoms in borderline personality disorder: developmental aspects, Current Opinion in Psychology, 37, 26, 10.1016/j.copsyc.2020.07.003 · DOI
- Chanen, 2012, Developmental pathways to borderline personality disorder, Current Psychiatry Reports, 14, 45, 10.1007/s11920-011-0242-y · DOI · Paper page
- Chanen, 2017, Prevention and early intervention for borderline personality disorder: a novel public health priority, World Psychiatry, 16, 215, 10.1002/wps.20429 · DOI · Paper page
- Coccaro, 1991, Development of neuropharmacologically-based behavioral assessments of impulsive aggressive behavior, Journal of Neuropsychiatry and Clinical Neurosciences, 3, S44
- Coccaro, 2020, The Overt Aggression Scale Modified (OAS-M) for clinical trials targeting impulsive aggression and intermittent explosive disorder: validity, reliability, and correlates, Journal of Psychiatric Research, 124, 50, 10.1016/j.jpsychires.2020.01.007 · DOI
- Crawford M Inclusion of your study in Cochrane review Email to: A Pathmanathan Ratnam
- Curtin, 2002, Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over, Statistics in Medicine, 21, 2161, 10.1002/sim.1207 · DOI · Paper page
- Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021), Cochrane 2021 Available from www.training.cochrane.org/handbook
- Derogatis, 1994, The Use of Psychological Testing for Treatment Planning and Outcome Assessment
- Deutsche Gesellschaft für Psychiatrie und Psychotherapie Psychosomatik und Nervenheilkunde (DGPPN) [German Association for Psychiatry, 2009, S2-Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1: Behandlungsleitlinie Persönlichkeitsstörungen [S2 Practical Guidelines in Psychiatry and Psychotherapy. Treatment Guideline Personality Disorders], 1
- Eaton, 2018, Personality disorders: community prevalence and socio-demographic correlates, Current Opinion in Psychology, 21, 28, 10.1016/j.copsyc.2017.09.001 · DOI
- Ellison, 2018, Community and clinical epidemiology of borderline personality disorder, Psychiatric Clinics of North America, 41, 561, 10.1016/j.psc.2018.07.008 · DOI · Paper page
- Gartlehner, 2021, Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis, Central Nervous System Drugs, 35, 1053, 10.1007/s40263-021-00855-4 · DOI
- Gartlehner, 2021, Authors’ reply to Pereira Ribeiro et al: comment on “Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis”, Central Nervous System Drugs, 35, 1335
- Goodman, 2012, Suicidal risk and management in borderline personality disorder, Current Psychiatry Reports, 14, 79, 10.1007/s11920-011-0249-4 · DOI
- Gunderson, 2011, Borderline personality disorder, New England Journal of Medicine, 364, 2037, 10.1056/NEJMcp1007358 · DOI · Paper page
- Guttierez, 2001, Development and initial validation of the Self-Harm Behavior Questionnaire, Journal of Personality Assessment, 77, 475, 10.1207/S15327752JPA7703_08 · DOI · Paper page
- Hancock-Johnson, 2017, A focused systematic review of pharmacological treatment for borderline personality disorder, Central Nervous System Drugs, 31, 345, 10.1007/s40263-017-0425-0 · DOI
- Hastrup, 2019, Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses, Acta Psychiatrica Scandinavica, 140, 458, 10.1111/acps.13094 · DOI · Paper page
- Herpertz, 2007, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders, World Journal of Biological Psychiatry, 8, 212, 10.1080/15622970701685224 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Higgins JPT Altmand DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston M, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org/handbook/archive/v5.2
- Ingenhoven, 2011, Differential effectiveness of antipsychotics in borderline personality disorder: Meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains, Journal of Clinical Psychopharmacology, 31, 489, 10.1097/JCP.0b013e3182217a69 · DOI
- Ingenhoven, 2015, Pharmacotherapy for borderline patients: business as usual or by default?, Journal of Clinical Psychiatry, 76, e522, 10.4088/JCP.14com09522 · DOI
- Jacobi, 2021, Disease burden of borderline personality disorder: cost of illness, somatic comorbidity and mortality, Nervenarzt, 92, 660, 10.1007/s00115-021-01139-4 · DOI
- Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
- Kjaergard, 2001, Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses, Annals of Internal Medicine, 135, 982, 10.7326/0003-4819-135-11-200112040-00010 · DOI · Paper page
- Knappich, 2014, Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices, International Clinical Psychopharmacology, 29, 224, 10.1097/YIC.0000000000000021 · DOI
- Kongerslev, 2015, Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research, Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 3, 31, 10.21307/sjcapp-2015-004 · DOI · Paper page
- 2020, Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project), Systematic Reviews, 9, 1
- Lau, 1995, Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care, Journal of Clinical Epidemiology, 48, 45, 10.1016/0895-4356(94)00106-Z · DOI · Paper page
- Levine, 1986, SAFTEE: a technique for the systematic assessment of side effects in clinical trials, Psychopharmacology Bulletin, 22, 343
- Linehan, 1997, Behavioral treatments of suicidal behaviors: definitional obfuscation and treatment outcomes, Annals of the New York Academy of Sciences, 836, 302, 10.1111/j.1749-6632.1997.tb52367.x · DOI · Paper page
- Links, 2009, Essentials of Personality Disorders, 343
- Mancke, 2015, Gender differences in aggression of borderline personality disorder, Borderline Personal Disord Emot Dysregul, 9, 7, 10.1186/s40479-015-0028-7 · DOI · Paper page
- Meuldijk, 2017, The value of psychological treatment for borderline personality disorder: Systematic review and cost offset analysis of economic evaluations, PLoS One, 1, e0171592, 10.1371/journal.pone.0171592 · DOI · Paper page
- Moher, 1999, Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses, Lancet, 354, 1896, 10.1016/S0140-6736(99)04149-5 · DOI · Paper page
- Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
- Montgomery, 1983, Dépression et Suicide: Aspects Medicaux, Psychologiques et Socio-Culturels, 786-90, 10.1016/B978-0-08-027080-7.50130-0 · DOI
- Mulder, 2021, CD-11 personality disorders: utility and implications of the new model, Front Psychiatry, 12, 655548, 10.3389/fpsyt.2021.655548 · DOI
- Munk-Jørgensen, 2010, Use of ICD-10 diagnoses in Danish psychiatric hospital-based services in 2001-2007, World Psychiatry, 9, 183, 10.1002/j.2051-5545.2010.tb00307.x · DOI · Paper page
- Neuroscience-Based Nomenclature Neuroscience-Based Nomenclature, Second Edition-reivsed https://nbn2r.com/search
- Neacsiu, 2017, Understanding borderline personality disorder across sociocultural groups: findings, issues, and future directions, Current Psychiatry Reviews, 13, 188, 10.2174/1573400513666170612122034 · DOI
- Newton-Howes, 2021, Personality disorder prevalence and correlates in a whole of nation dataset, Soc Psychiatry Psychiatr Epidemiol, 56, 679, 10.1007/s00127-020-01876-y · DOI
- Ng, 2016, Recovery from borderline personality disorder: a systematic review of the perspectives of consumers, clinicians, family and carers, PLoS One, 11, e0160515, 10.1371/journal.pone.0160515 · DOI
- National Health and Medical Research Council, 2013, Clinical Practice Guideline for the Management of Borderline Personality Disorder
- Niesten, 2016, Description and prediction of the income status of borderline patients over 10 years of prospective follow-up, Personality and Mental Health, 10, 285, 10.1002/pmh.1331 · DOI · Paper page
- Ose, 2021, Non-suicidal self-injury (NSSI) in adult psychiatric outpatients - a nationwide study, Journal of Psychiatric Research, 133, 1, 10.1016/j.jpsychires.2020.11.031 · DOI
- Ottosson, 2002, Cross-system concordance of personality disorder diagnoses of DSM-IV and diagnostic criteria for research of ICD-10, Journal of Personality Disorders, 16, 283, 10.1521/pedi.16.3.283.22537 · DOI
- Oud, 2018, Specialized psychotherapies for adults with borderline personality disorder: A systematic review and meta-analysis, Aust N Z J Psychiatry, 52, 949, 10.1177/0004867418791257 · DOI · Paper page
- Overall, 1962, The Brief Psychiatric Rating Scale, Psychological Reports, 10, 799, 10.2466/pr0.1962.10.3.799 · DOI · Paper page
- Paris, 2015, Why patients with severe personality disorders are overmedicated, Journal of Clinical Psychiatry, 76, e521, 10.4088/JCP.14com09441 · DOI
- Pascual, 2021, Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain., CNS Drugs, 35, 1023, 10.1007/s40263-021-00852-7 · DOI
- Paton, 2015, The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK Mental Health Services, Journal of Clinical Psychiatry, 76, e512-8, 10.4088/JCP.14m09228 · DOI · Paper page
- Comment on: “Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis” CNS Drugs 35 1333 1334 https://doi.org/10.1007/s40263-021-00872-3 · DOI
- Perez, 2007, The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes, Actas Españolas de Psiquiatría, 35, 229
- Review Manager Web (RevMan Web) The Cochrane Collaboration 2020
- Riffer, 2019, Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines, International Journal of Psychiatry in Clinical Practice, 23, 178, 10.1080/13651501.2019.1576904 · DOI
- Schneider, 2019, Mortality and medical comorbidity in the severely mentally ill, Deutsches Arzteblatt International, 116, 405, 10.3238/arztebl.2019.0405 · DOI · Paper page
- Schulz, 1995, Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.273.5.408 · doi:10.1001/jama.273.5.408
- Schulz, 2008, Olanzapine for the treatment of borderline personality disorder: variable dose, 12-week, randomised double-blind placebo-controlled study, British Journal of Psychiatry, 193, 485-92, 10.1192/bjp.bp.107.037903 · DOI · Paper page
- Sher, 2019, Gender differences and similarities in aggression, suicidal behaviour, and psychiatric comorbidity in borderline personality disorder, Acta Psychiatr Scand, 139, 145, 10.1111/acps.12981 · DOI
- Silk, 2015, Management and effectiveness of psychopharmacology in emotionally unstable and borderline personality disorder, Journal of Clinical Psychiatry, 76, e524-5, 10.4088/JCP.14com09534 · DOI
- Soloff, 2002, Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder, Journal of Personality Disorders, 16, 201, 10.1521/pedi.16.3.201.22542 · DOI · Paper page
- Soloff, 2012, Prospective predictors of suicidal behavior in borderline personality disorder at 6-year follow-up, Am J Psychiatry, 169, 484, 10.1176/appi.ajp.2011.11091378 · DOI · Paper page
- Spielberger, 1988, Manual for the State-Trait Anger Expression Inventory
- Stepp, 2012, Development of borderline personality disorder in adolescence and young adulthood: introduction to the special section, Journal of Abnormal Child Psychology, 40, 1, 10.1007/s10802-011-9594-3 · DOI · Paper page
- Sterne JA Why the Cochrane risk of bias tool should not include funding source as a standard item Cochrane Database of Systematic Reviews 2013 12 ED000076 10.1002/14651858.ED000076 24575440 · DOI · Paper page
- Sterne JAC Egger M Moger D Boutron I Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org/handbook
- Stiglmayr, 2005, Aversive tension in patients with borderline personality disorder: a computer-based controlled field study, Acta Psychiatrica Scandinavica, 111, 372, 10.1111/j.1600-0447.2004.00466.x · DOI · Paper page
- Stoffers, 2015, Pharmacotherapy for borderline personality disorder--current evidence and recent trends, Current Psychiatry Reports, 17, 534, 10.1007/s11920-014-0534-0 · DOI
- Stoffers-Winterling, 2018, Pharmacological interventions for people with borderline personality disorder, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012956 · DOI
- Stoffers-Winterling, 2020, Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies, Current Psychiatry Reports, 22, 37, 10.1007/s11920-020-01164-1 · DOI · Paper page
- Stoffers-Winterling J Cochrane Collaboration review - RCT of escitalopram in BPD Email to: E Coccaro
- Stone, 1993, Long-term outcome in personality disorders, British Journal of Psychiatry, 162, 299, 10.1192/bjp.162.3.299 · DOI · Paper page
- Storebø, 2014, Is ADHD an early stage in the development of borderline personality disorder?, Nordic Journal of Psychiatry, 68, 289, 10.3109/08039488.2013.841992 · DOI · Paper page
200 of 220 shown
Cited by
Leichsenring, F., Fonagy, P., Heim, N., Kernberg, O. F., Leweke, F., Luyten, P., Salzer, S., Spitzer, C., & Steinert, C. (2024) · World Psychiatry · doi:10.1002/wps.21156 · Cited by 294
Borderline Personality Disorder: A Review
Leichsenring, F., Heim, N., Leweke, F., Spitzer, C., Steinert, C., & Kernberg, O. F. (2023) · JAMA · doi:10.1001/jama.2023.0589 · Cited by 221
Early intervention for personality disorder
Chanen, A. M., Sharp, C., Nicol, K., & Kaess, M. (2022) · Focus · doi:10.1176/appi.focus.20220062 · Cited by 38
Pharmacological management of personality disorders: from evidence to practice
Völlm, B., & Cerci, D. (2025) · BJPsych Advances · doi:10.1192/bja.2024.30 · Cited by 4
Positive Self-Relation Scale – development and psychometric properties
Ociskova, M., Prasko, J., & Kupka, M. (2019) · Psychology Research and Behavior Management · doi:10.2147/prbm.s212923 · Cited by 2
Metadata
- Authors
- Stoffers-Winterling, J. M., Storebø, O. J., Pereira Ribeiro, J., Kongerslev, M. T., Völlm, B. A., Mattivi, J. T., Faltinsen, E., Todorovac, A., Jørgensen, M. S., Callesen, H. E., Sales, C. P., Schaug, J. P., Simonsen, E., & Lieb, K.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2022-11-14
- Volume
- 2022
- Issue
- 11
- Pages
- CD012956-CD012956
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W4308964737
- Cited by
- 108
- References
- 71
- FWCI
- 18.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.